Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.

Front Immunol · 2022 · PMC9556706 · PMID 36248913

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Our analysis demonstrated that in patients with active RA, JAKi, in combination with MTX, was more prone to attain remission and low disease activity than JAKi monotherapy, although most indexes were associated with a favorable trend of response rate without a significant difference.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.